These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 24708767)
1. Genetic variability of the core protein in hepatitis C virus genotype 4 in Saudi Arabian patients and its implication on pegylated interferon and ribavirin therapy. Alhamlan FS; Al-Ahdal MN; Khalaf NZ; Abdo AA; Sanai FM; Al-Ashgar HI; ElHefnawi M; Zaid A; Al-Qahtani AA J Transl Med; 2014 Apr; 12():91. PubMed ID: 24708767 [TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus genotype 1: how genetic variability of the core protein affects the response to pegylated-interferon and ribavirin therapy. Alhamlan FS; Al-Ahdal MN; Khalaf NZ; Abdo AA; Sanai FM; Al-Ashgar HI; Elhefnawi M; Zaid A; Al-Qahtani AA J Med Virol; 2014 Feb; 86(2):224-34. PubMed ID: 24166351 [TBL] [Abstract][Full Text] [Related]
3. NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients. El-Shamy A; Shoji I; El-Akel W; Bilasy SE; Deng L; El-Raziky M; Jiang DP; Esmat G; Hotta H J Clin Microbiol; 2012 Dec; 50(12):3886-92. PubMed ID: 22993188 [TBL] [Abstract][Full Text] [Related]
4. Sustained virologic response to standard interferon or pegylated interferon and ribavirin in patients with hepatitis C virus genotype 5: systematic review and meta-analysis of ten studies and 423 patients. Devaki P; Jencks D; Yee BE; Nguyen MH Hepatol Int; 2015 Jul; 9(3):431-7. PubMed ID: 26016464 [TBL] [Abstract][Full Text] [Related]
5. Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment. Bolcic F; Sede M; Moretti F; Westergaard G; Vazquez M; Laufer N; Quarleri J Arch Virol; 2012 Apr; 157(4):703-11. PubMed ID: 22270759 [TBL] [Abstract][Full Text] [Related]
6. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715 [TBL] [Abstract][Full Text] [Related]
7. [Genomic diversity of the genotype 1b hepatitis C virus open reading frame is correlated with outcomes of combined pegylated-interferon/ribavirin therapy in patients with chronic hepatitis C from Henan Province]. Zeng Y; Kang Y; Shang J Zhonghua Gan Zang Bing Za Zhi; 2014 Jun; 22(6):401-6. PubMed ID: 25203700 [TBL] [Abstract][Full Text] [Related]
8. Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life? Gonçales FL; Moma CA; Vigani AG; Angerami AF; Gonçales ES; Tozzo R; Pavan MH; Gonçales NS BMC Infect Dis; 2010 Jul; 10():212. PubMed ID: 20646277 [TBL] [Abstract][Full Text] [Related]
9. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study. Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225 [TBL] [Abstract][Full Text] [Related]
10. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356 [TBL] [Abstract][Full Text] [Related]
11. Peg-interfon alpha-2a and low-dose ribavirin for treatment of hepatitis C virus infection in patients with sickle-cell anemia in Saudi Arabia. Agha A; Chakik R; Abdulhadi Ali MM; Alsaudi D; Sammito G; Giannini EG Ann Saudi Med; 2013; 33(6):610-3. PubMed ID: 24413867 [TBL] [Abstract][Full Text] [Related]
12. Influence of amino acid variations in the NS3, NS4A and NS4B of HCV genotypes 1a, 1b, 3a, 3b and 6f on the response to pegylated interferon and ribavirin combination therapy. Chusri P; Kumthip K; Pantip C; Thongsawat S; O'Brien A; Maneekarn N Virus Res; 2015 Jan; 196():37-43. PubMed ID: 25445343 [TBL] [Abstract][Full Text] [Related]
13. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448 [TBL] [Abstract][Full Text] [Related]
14. Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load. Kim SR; El-Shamy A; Imoto S; Kim KI; Ide YH; Deng L; Shoji I; Tanaka Y; Hasegawa Y; Ota M; Hotta H J Gastroenterol; 2012 Oct; 47(10):1143-51. PubMed ID: 22441534 [TBL] [Abstract][Full Text] [Related]
15. Consensus guidelines for the management of hepatitis C infection. Consensus Guidelines Committee for the Management of Hepatitis C Infection Saudi Med J; 2003 Jul; 24 Suppl 2():S99-118. PubMed ID: 25121186 [TBL] [Abstract][Full Text] [Related]
16. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy. Singal AG; Waljee AK; Shiffman M; Bacon BR; Schoenfeld PS Aliment Pharmacol Ther; 2010 Oct; 32(8):969-83. PubMed ID: 20937042 [TBL] [Abstract][Full Text] [Related]
17. Amino acid sequence analysis in patients with chronic HCV genotype 1b infection during pegylated interferon-α2a and ribavirin therapy. Fu JJ; Kong WJ; Jiang D; Pan XC; Wei L Antivir Ther; 2014; 19(7):661-8. PubMed ID: 24584067 [TBL] [Abstract][Full Text] [Related]
18. Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma. Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H J Med Virol; 2008 Aug; 80(8):1354-62. PubMed ID: 18551609 [TBL] [Abstract][Full Text] [Related]
19. Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene. Toyoda H; Kumada T; Hayashi K; Honda T; Katano Y; Goto H; Kawaguchi T; Murakami Y; Matsuda F J Med Virol; 2011 Sep; 83(9):1559-64. PubMed ID: 21739446 [TBL] [Abstract][Full Text] [Related]
20. Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load. Toyoda H; Kumada T; Tada T; Arakawa T; Hayashi K; Honda T; Katano Y; Goto H J Gastroenterol Hepatol; 2010 Jun; 25(6):1072-8. PubMed ID: 20594221 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]